FIELD: biotechnology.
SUBSTANCE: following is described: a group of inventions including an antibody to CLDN18.2 or an antigen-binding fragment thereof, a nucleic acid encoding the above antibody, a method of producing an antibody to CLDN18.2 or an antigen-binding fragment thereof, the use of an antibody to CLDN18.2 or an antigen-binding fragment thereof in the manufacture of a medicinal product for a specific targeting tumor cells expressing CLDN18.2, or a diagnostic reagent for detecting tumors expressing CLDN18.2 and a method of detecting expression of CLDN18.2 in a sample.
EFFECT: invention expands the arsenal of agents that specifically bind to IL-2.
10 cl, 37 dwg, 14 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| COMPOSITIONS AND METHODS FOR MODULATING THE TRANSMISSION OF A LAIR SIGNAL | 2017 |
|
RU2757394C2 |
